Red blood cell-encapsulated L-asparaginase: Potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia

Protein and Peptide Letters

Volumn 20, Issue 4, 2013, Pages 392-402

  Agrawal, Vaidehi ^a   Woo, Jung Hee ^a   Borthakur, Gautham ^b   Kantarjian, Hagop ^b   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

L asparaginase and AML; Red blood cell encapsulation

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARTATE AMMONIA LIGASE; BIOLOGICAL MARKER; CELL PROTEIN; CORTICOSTEROID; CYTOTOXIC AGENT; DEXAMETHASONE; GENERAL CONTROL NON DEREPRESSIBLE 2 KINASE; GRASPA; MESSENGER RNA; METHOTREXATE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER RESISTANCE; CELL ENCAPSULATION; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; EPIGENETICS; GENE EXPRESSION; GENE LOCATION; GENETIC REGULATION; HUMAN; HYPERGLYCEMIA; NEUROLOGIC DISEASE; NK T CELL LYMPHOMA; NONHUMAN; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PHYSICAL CHEMISTRY; PROTEIN DEPLETION; PROTEIN SYNTHESIS; RED BLOOD CELL ENCAPSULATION; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; THROMBOSIS;

ASPARAGINASE; ASPARAGINE; ASPARTATE-AMMONIA LIGASE; DRUG CARRIERS; DRUG DISCOVERY; EPIGENESIS, GENETIC; ERYTHROCYTES; HUMANS; LEUKEMIA, MYELOID, ACUTE; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84877948067     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986613805290426     Document Type: Review

References (92)

1. Kidd, J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Courses of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum or rabbit serum. J. Exp. Med., 1953, 95, 565-582.
2. Broome, J.D. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature, 1961, 191, 1114-1115.
3. Old, L.J.; Boyse, E.A.; Campbell, H.A.; Daria, G.M. Leukemiainhibiting properties and L-asparaginase activity of sera from certain South American rodents. Nature, 1963, 198, 801.
4. Mashburn, L.T.; Wriston, J.C. Tumor inhibitory effect of Lasparaginase from Escherichia coli. Arch. Biochem., 1964, 105, 451-452.
5. Old, L.J.; Boyse, E.A.; Campbell, H.A. L-asparagine and leukemia. Scientific Am., 1968, 219, 34-40.
6. Old, L.J.; Boyse, E.A.; Campbell, H.A.; Brodey, R.S.; Fidler, I.J.; Teller, J.D. Treatment of lymphosarcoma in the dog with Lasparaginase. Cancer, 1967, 20, 1066-1070.
7. Oettgen, H.F.; Old, L.J.; Boyse, E.A.; Campbell, H.A.; Phillips, F.S.; Clarkson, B.D.; Tallal, L.; Leeper, R.D.; Schwartz, M.K.; Kim, J.H. Inhibition of leukemias in man by L-asparaginase. Cancer Res., 1967, 27, 2619-2931.
8. Hill, J.M.; Roberts, J.; Loeb, E.; Khan, A.; MacLellan, A.; Hill, R.W. L-asparaginase therapy for leukemia and other malignant neoplasms: remission in human leukemia. JAMA, 1967, 202, 882-888.
9. Horowitz, B.; Madras, B.K.; Meister, A.; Old, L.J.; Boyse, E.A.; Stockert, E. Asparagine synthetase activity of mouse leukemias. Science, 1968, 160, 533-535.
10. Haskell, C.M.; Canellos, G.P. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharmacol., 1969, 18, 2578-2580.
11. Pieters, R.; Hunger, S.P.; Boos, J.; Rizzari, C.; Silverman, L.; Baruchel, A.; Goekbuget, N.; Schrappe, M.; Pui, C.H. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer, 2011, 117, 238-249.
12. Taylor, C.W.; Dorr, R.T.; Fanta, P.; Hersh, E.M.; Salmon, S.E. A phase I and pharmacodynamic evaluation of polyethylene glycolconjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2001, 47, 83-88.
13. Abshire, T.C.; Pollock, B.H.; Billett, A.L.; Bradley, P.; Buchanan, G.R. Weekly pegylated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood, 2000, 96, 1709-1715.
14. Wetzler, M.; Sanford, B.L.; Kutzberg, L.; DeOliveira, D.; Frankel, S.R.; Powell, B.L.; Kolitz, J.E.; Bloomfield, C.D.; Larson, R.A. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study 9511. Blood, 2007, 109, 4164-4167.
15. Wang, R.; Xia, B.; Li, B.J.; Peng, S.L.; Ding, L.S.; Zhang, S. Semipermeable nanocapsules of konjac glucomannan-chitosan for enzyme immobilization. Int. J. Pharm., 2008, 364(1), 102-107.
16. Teodor, E.; Litescu, S.C.; Lazar, V.; Somoghi, R. Hydrogelmagnetic nanoparticles with immobilized L-asparaginase for biomedical applications. J. Mater. Science, 2009, 20, 1307-1314.
17. Hamidi, M. Carrier Erythrocytes: An Overview. Drug Deliv., 2003, 10, 9-20.
18. Kravtzoff, R.; Desbois, I.; Lamagnese, J.P.; Muh, J.P.; Valat, C.; Chassaigne, M.; Colombat, P.; Ropars, C. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur. J. Clin. Pharmacol., 1996, 49(6), 465-470.
19. Clementi, A. La desamidation enzymatique de lasparagine chez les differentes especes animals et la signification physiologique de sa presence dans lorganisme. Arch. Intern. Physiol., 1922; 19, 369.
20. Lubkowski, J.; Dauter, M.; Aghaiypour, K.; Wlodawer, A.; Dauter, Z. Atomic resolution structure of Erwinia chrysanthemi Lasparaginase. Acta Crystallographica Section D, 2003, 59, 84-92.
21. Palm, G.J.; Lubkowski, J.; Derst, C.; Schleper, S.; Rohm, K.H.; Wlodawer, A. A covalently bound catalytic intermediate in Escherichia coli asparaginase: crystal structure of a Thr-89-Val mutant. FEBS Lett., 1996, 399, 211-216.
22. Aghaiypour, K.; Wlodawer, A.; Lubkowski, J. Structural basis for the activity and substrate specificity of Erwinia chrysanthemi Lasparaginase. Biochemistry, 2001, 40, 5655-5664.
23. Offman, M.N.; Krol, M.; Patel, N.; Krishnan, S.; Liu, J.; Saha, V.; Bates, P.A. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood, 2011, 117, 1614-1621.
24. Kotzia, G.A.; Labrou, N.E. Engineering thermal stability of Lasparaginase by in vitro directed evolution. FEBS J., 2009, 276, 1750-1761.
25. Labrou, N.E.; Papageorgiou, A.C.; Avramis, V.I. Structurefunction relationships and clinical applications of L-asparaginases. Curr. Med. Chem., 2010, 17, 2183-2195.
26. Patel, N.; Krishnan, S.; Offman, M.N.; Krol, M.; Moss, C.X.; Leighton, C.; van Delft, F.W.; Holland, M.; Liu, J.Z.; Alexander, S.; Dempsey, C.; Ariffin, H.; Essink, M.; Eden, T.O.B.; Watts, C.; Bates, P.A.; Saha, V. A dyad of lymphoblastic lysosomal cystein proteases degrades the antileukemic drug L-asparaginase. J. Clin. Invest., 2009, 119, 1964-1973.
27. Offman, M.N.; Krol, M.; Patel, N.; Krishnan, S.; Liu, J.Z.; Saha, V.; Bates, P.A. Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell cytotoxicity. Blood, 2010 [Epub ahead of print]
28. Armstrong, J.K.; Hempel, G.; Koling, S.; Chan, L.S.; Fisher, T.; Meiselman, H.J.; Garratty, G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 2007, 110, 103-111.
29. Dinndorf, P.A.; Gootenberg, J.; Cohen, M.H.; Keegan, P.; Pazdur, R. FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist, 2007, 12, 991-998.
30. Cantor, J.R.; Stone, E.M.; Chantranupong, L.; Georgiou, G. The human asparaginase-like protein 1 hASRGL1 is an Ntn hydrolase with beta-aspartyl peptidase activity. Biochemistry, 2009, 48, 11026-11031.
31. Cantor, J.R.; Yoo, T.H.; Dixit, A.; Iverson, B.L.; Forsthuber, T.G.; Georgiou, G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc. Natl. Acad. Sci USA, 2011, 108, 1272-1277.
32. Larsen, T.M.; Boehlein, S.K.; Schuster, S.M.; Richards, N.G.J.; Thoden, J.B.; Holden, H.M.; Rayment, I. Three-dimensional structure of Escherichia coli asparagine synthetase B: a short journey from substrate to product. Biochemistry, 1999, 38, 16146-16157.
33. Leslie, M.; Case, M.C.; Hall, A.G.; Coulthard, S.A. Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br. J. Haematol., 2006, 132, 740-742.
34. Su, N.; Pan, Y.X.; Zhou, M.; Harvey, R.C.; Hunger, S.P.; Kilberg, M.S. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr. Blood Cancer, 2008, 50, 274-279.
35. Haskell, C.M.; Canellos, G.P. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharmacol., 1969, 18, 2578-2580.
36. Scherf, U.; Ross, D.T.; Waltham, M.; Smith, L.H.; Lee, J.K.; Tanabe, L.; Kohn, K.W.; Reinhold, W.C.; Myers, T.G.; Andrews, D.T.; Scudiero, D.A.; Eisen, M.B.; Sausville, E.A.; Pommier, Y.; Botstein, D.; Brown, P.O.; Weinstein, J.N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 2000, 24, 236-244.
37. Lorenzi, P.L.; Llamas, J.; Gunsior, M.; Ozbun, L.; Reinhold, W.C.; Varma, S.; Ji, H.; Kim, H.; Hutchinson, A.A.; Kohn, E.C.; Goldsmith, P.K.; Birrer, M.J.; Weinstein, J.N. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol. Cancer Ther., 2008, 7, 3123-3128.
38. Chen, S.H.; Yang, W.; Fan, Y.; Stocco, G.; Crews, K.R.; Yang, J.J.; Paugh, S.W.; Pui, C.H.; Evans, W.E.; Relling, M.V. A genome- wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia, 2011, 25, 66-74.
39. Peng, H.; Shen, N.; Qian, L.; Sun, X.L.; Koduru, P.; Goodwin, L.O.; Issa, J.P.; Broom, M.D. Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells. Br. J. Cancer, 2001, 85, 930-935.
40. Ding, Y.; Li, Z.; Broome, J.D. Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines. Leukemia, 2005, 19, 420-426.
41. Ren, Y.; Roy, S.; Ding, Y.; Iqbal, J.; Broome, J.D. Methylation of the asparagine synthetase promoter in human leukemic cell lines is associated with a specific methyl binding protein. Oncogene, 2004, 23, 3953-3961.
42. Wang, B.; Relling, M.V.; Storm, M.C.; Woo, M.H.; Ribeiro, R.; Pui, C.H.; Hak, L.J. Evaluation of immunologic crossreaction of anti-asparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia, 2003, 17, 1583-1588.
43. Iwamoto, S.; Mihara, K.; Downing, J.R.; Pui, C.H.; Campana, D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest., 2007, 117, 1049-1057.
44. Padyana, A.K.; Qiu, H.; Roll-Mecak, A.; Hinnebusch, A.G.; Burley, S.K. Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J. Biol. Chem., 2005, 280, 29289-29299.
45. Wek, R.C.; Jiang, H.Y.; Anthony, T.G. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans., 2006, 34, 7-11.
46. Fafournoux, P.; Bruhat, A.; Jousse, C. Amino acid regulation of gene expression. Biochem. J., 2000, 351, 1-12.
47. Lopez, A.B.; Wang, C.; Huang, C.C.; Yaman, I.; Li, Y.; Chakravarty, K.; Johnson, P.F.; Chiang, C.M.; Snider, M.D.; Wek, R.C.; Hatzoglou, M. A feedback transcriptional mechanism controls the level of the arginine/lysine transporter cat-1 during amino acid starvation. Biochem. J., 2007, 402, 163-173.
48. Rzymski, T.; Milani, M.; Pike, et al., Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene, 2010, 29, 4424-4435.
49. Richards, N.G.; Kilberg, M.S. Asparagine synthetase chemotherapy. Annual Rev. Biochem., 2006,. 75, 629-654.
50. Avramis, V.I.; Panosyan, E.H. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations. Clin. Pharmacokinet., 2005, 44, 367-393.
51. Rytting, M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin. Biol. Ther., 2010, 10, 833-839.
52. Hernandez-Espinosa, D.; Minano, A.; Ordonez, A.; Mota, R.; Martinez-Martinez, I.; Vicente, V.; Corral, J. Dexamethasone induces a heat-stress response that ameliorates the conformational consequences on antithrombin of L-asparaginase treatment. J. Thromb. Haemost., 2009, 7, 1128-1133.
53. Grace, R.F.; Dahlberg, S.E.; Neuberg, D.; Sallan, S.E.; Conners, J.M.; Neufeld, E.J.; Deangelo, D.J.; Silverman, L.B. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br. J. Haematol., 2011, 152, 452-459.
54. Dinndorf, P.A.; Gootenberg, J.; Cohen, M.H.; Keegan, P.; Pazdur, R. FDA drug approval summary: pegasparagase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist, 2007, 12, 991-998.
55. Tong, H.; Ren, Y.; Qian, W.; Xiao, F.; Mai, W.; Meng, H.; Jin, J. Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. Int. J. Hematol., 2009, 90, 303-310.
56. Takahashi, T.; Ikejiri, F.; Onishi, C.; Kawakami, K.; Inoue, M.; Miyake, T.; Tanaka, J.; Araki, A.; Maruyama, R.; Ohshima, K.; Suzumiya, J. L-asparaginase-induced complete response in a relapsed patient with Epstein-Barr virus and cytotoxic peripheral Tcell lymphoma not otherwise specified. Intern. Med., 2010, 49, 2505-2508.
57. Obama, K.; Tara, M.; Niina, K. L-asparaginase induced complete remission in Epstein-Barr virus positive, multidrug resistant, cutaneous T-cell lymphoma. Int. J. Hematol., 1999, 69, 260-262.
58. Taylor, C.W.; Dorr, R.T.; Fanta, P.; Hersh, E.M.; Salmon, S.E. A phase I and pharmacodynamic evaluation of polyethylene glycolconjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother. Pharmacol., 2001, 47, 83-88.
59. Tallal, L.; Tan, C.; Oettgen, H.; Wollner, N.; McCarthy, M.; Helson, L.; Burchenal, J.; Karnofsky, D.; Murphy, M.L. E. coli Lasparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer, 1970, 25, 306-320.
60. Clarkson, B.; Krakoff, I.; Burchenal, J.; Karnofsky, D.; Golbey, R.; Dowling, M.; Oettgen, H.; Lipton, A. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors. Cancer, 1970, 25, 279-305.
61. Pratt, C.B.; Simone, J.V.; Zee, P.; Aur, R.J.; Johnson, W.W. Comparison of daily versus weekly L-asparaginase for the treatment of childhood acute leukemia. J. Pediatr., 1970, 77, 474-483.
62. Capizzi, R.L.; Bertino, J.R.; Skeel, R.T.; Creasey, W.A.; Zanes, R.; Olayon, C.; Peterson, R.G.; Handschumacher, R.E. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann. Intern. Med., 1971, 74, 893-901.
63. Ertel, I.J.; Nesbit, M.E.; Hammond, D.; Weiner, J.; Sather, H. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphoblastic leukemia: a report from Childrens Cancer Study Group. Cancer Res., 1979, 39, 3893-3896.
64. Ettinger, L.J.; Kurtzberg, J.; Voute, P.A.; Jurgens, H.; Halpern, S.L. An open-label, multicenter study of polyethylene glycol-Lasparginase for the treatment of acute lymphoblastic leukemia. Cancer, 1995, 75, 1176-1181.
65. Aguayo, A.; Cortes, J.; Thomas, D.; Pierce, S.; Keating, M.; Kantarjian, H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer, 1999, 86, 1203-1209.
66. Jaccard, A.; Gachard, N.; Marin, B.; Rogez, S.; Audrain, M.; Suarez, F.; Tilly, H.; Morschhauser, F.; Thieblemont, C.; Ysebaert, L.; Devidas, A.; Petit, B.; de Leval, L.; Gaulard, P.; Feuillard, J.; Bordessoule, D.; Hermine, O. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood, 2011, 117, 1834-1839.
67. Kitoh, T.; Sawada, M.; Shirahase, H.; Harnahata, K.; Usami, I.; Ying-Wei, L.; Akiyama, Y.; Kubota, M.; Schuster, S.M. Asparagine synthetase protein expression in leukemia cells: application of L-asparaginase treatment for leukemia. Blood, 1998, 92 Suppl 1, 400a.
68. Su, N.; Pan, Y.X.; Zhou, M.; Harvey, R.C.; Hunger, S.P.; Kilberg, M.S. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr. Blood Cancer, 2008, 50, 274-279.
69. Lorenzi, P.L.; Llamas, J.; Gunsior, M.; Ozbun, L.; Reinhold, W.C.; Varma, S.; Ji, H.; Kim, H.; Hutchinson, A.A.; Kohn, E.C.; Goldsmith, P.K.; Birrer, M.J.; Weinstein, J.N.; Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol. Cancer Ther., 2008, 7, 3123-3128.
70. Haskell, C.M.; Canellos, G.P. L-asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharmacol., 1969, 18, 2578-2580.
71. Dubbers, A.; Wurthwein, G.; Muller, H.J.; Schulze-Westhoff, P.; Winkelhorst, M.; Kurzknabe, E.; Lanvers, C.; Pieters, R.; Kaspers, G.J.L.; Creutzig, U.; Ritter, J.; Boos, J. Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br. J. Haematol., 2000, 109, 427-429.
72. Codegoni, A.M.; Biondi, A.; Conter, V.; Masera, G.; Rambaldi, A.; D'Incalci, M. Human monocytic leukemia expresses low levels of asparagine synthetase and is potentially sensitive to L-asparaginase. Leukemia, 1995, 9, 360-361.
73. Leslie, M.; Case, M.C.; Hall, A.G.; Coulthard, S.A.; Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br. J. Haematol., 2006, 132, 740-742.
74. Irino, T.; Kitoh, T.; Koami, K.; Kashima, T.; Mukai, K.; Takeuchi, E.; Hongo, T.; Nakahata, T.; Schuster, S.M.; Osaka, M. Establishment of real-time polymerase chain reaction method for quantitative analysis of asparagine synthetase expression. J. Mol. Diagn., 2004, 6, 217-224.
75. Schrek, R.; Dolowy, W.C. In vitro test for sensitivity of leukemic cells to L-asparaginase. Cancer Res., 1971, 31, 523-526.
76. Zwaan, C.M.; Kaspers, G.J.L.; Pieters, R.; Ramakers-Van Woerden, N.L.; den Boer, M.L.; Wunsche, R.; Rottier, M.M.A.; Hahlen, K.; van Wering, E.R.; Janka-Schaub, G.E.; Creutzig, U.; Veerman, A.J.P. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood, 2000, 96, 2879-2886.
77. Yamada, S.; Hongo, T.; Okada, S.; Watanabe, C.; Fujii, Y.; Ohzeki, T. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia, 2001, 15, 1892-1897.
78. Okada, S.; Hongo, T.; Yamada, S.; Watanabe, C.; Fujii, Y.; Ohzeki, T.; Horikoshi, Y.; Ito, T.; Yazaki, M.; Komada, Y. In vitro efficacy of L-asparaginase in childhood acute myeloid leukaemia. Br. J. Haematol., 2003, 123, 802-809.
79. Chen, S.H.; Yang, W.; Fan, Y.; Stocco, G.; Crews, K.R.; Yang, J.J.; Paugh, S.W.; Pui, C.H.; Evans, W.E.; Relling, M.V. A genome- wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia, 2011, 25, 66-74.
80. Updike, S.J.; Wakamiya, R.T. Infusion of red blood cell-loaded asparaginase in monkey. J. Lab. Clin. Med., 1983, 101, 679-691.
81. Naqi, A.; DeLoach, J.R.; Andrews, K.; Satterfield, W.; Keeling, M. Determination of parameters for enzyme therapy using Lasparaginase entrapped in canine erythrocytes. Biotechnol. Appl. Biochem., 1988, 10, 365-372.
82. Alpar, H.O.; Lewis, D.A. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem. Pharmacol., 1985, 34, 257-261.
83. Kravtzoff, R.; Ropars, C.; Laguerre, M.; Muh, J.P.; Chassaigne, M. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in vivo studies. J. Pharm. Pharmacol., 1990, 42, 473-476.
84. Ataullakhanov, F.I.; Vitvitskii, V.M.; Zhabotinskii, A.M.; Pichugin, A.V. Permeability of human erythrocytes to asparagine. Biokhimiya, 1986, 50, 1480-1484.
85. Kravtzoff, R.; Colombat, P.H.; Desbois, I.; Linassier, C.; Muh, J.P.; Philip, T.H.; Blay, J.Y.; Gardenbas, M.; Poumier-Gaschard, P.; Lamargnere, J.P.; Chassaigne, M.; Ropars, C. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur. J. Clin. Pharmacol., 1996, 51, 221-225.
86. Kravtzoff, R.; Desbois, I.; Lamagnere, J.P.; Muh, J.P.; Valat, C.; Chassaigne, M.; Colombat, P.; Ropars, C. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur. J. Clin. Pharm., 1996, 49, 465-470.
87. Domenech, C.; Thomas, X.; Chabaud, S.; Baruchel, A.; Gueyffier, F.; Mazingue, F.; Auvrignon, A.; Corm, S.; Dombret, H.; Chevallier, P.; Galambrun, C.; Huguet, F.; Legrand, F.; Mechinaud, F.; Vey, N.; Philip, I.; Liens, D.; Godfrin, Y.; Rigal, D.; Bertrand, Y. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br. J. Haematol., 2011, Epub Feb 20.
88. Kantarjian, H.; Schiffer, C.; Burnett, A. Hematologic malignancies: where do we stand in 2011? J. Clin. Oncol., 2011, 29, 473-474.
89. Capizzi, R.L.; Davis, R.; Powell, B.; Cuttner, J.; Ellison, R.R.; Cooper, M.R.; Dillman, R.; Major, W.B.; Dupre, E.; McIntyre, O.R. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia-a Cancer and Leukemia Group B study. J. Clin. Oncol., 1988, 6, 499-508.
90. Delage, B.; Fennell, D.A.; Nicholson, L.; McNeish, I.; Lemoine, N.R.; Crook, T.; Szlosarek, P.W. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int. J. Cancer, 2010, 126, 2762-2772.
91. Hu, J.; Cheung, N.K.V. Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs. Int. J. Cancer, 2009, 124, 1700-1706.
92. Godfrin, Y.; Bertrand, Y. L-asparaginase introduced into erythrocytes for the treatment of leukaemia (ALL). Oncol. News, 2006, 1, 2-5.